Literature DB >> 7777207

ATP release evoked by isoprenaline from adrenergic nerves of guinea pig atrium.

T Tokunaga1, T Katsuragi, C Sato, T Furukawa.   

Abstract

Mode and site of release of ATP evoked by isoprenaline were evaluated in the electrically driven left atrial segment of guinea pig. The peak release of ATP 5 min after 1 microM isoprenaline was inhibited by 1 microM propranolol and 1 microM butoxamine, but not by 1 microM atenolol, showing that the ATP release is due to stimulation of the presynaptic beta 2-adrenoceptor by isoprenaline. The maximum ATP release was markedly reduced by Ca2+/calmodulin antagonists, W-7 and trifluoperazine, and by a mitotic inhibitor, vinblastine. Further, the release was similarly inhibited by myosin light chain kinase inhibitors, ML-7 and wortmannin. Nifedipine, a Ca(2+)-channel blocker, decreased the release of ATP evoked by isoprenaline. By contrast, Bay K 8644, a Ca(2+)-channel opener, tended to enhance the ATP release. These findings suggest that isoprenaline produces ATP release from adrenergic nerve terminals of atrium, implying that ATP serves as a co-transmitter.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777207     DOI: 10.1016/0304-3940(95)11290-d

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Selective enhancement of the slow component of delayed rectifier K+ current in guinea-pig atrial cells by external ATP.

Authors:  H Matsuura; T Ehara
Journal:  J Physiol       Date:  1997-08-15       Impact factor: 5.182

Review 2.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

3.  The Ionotropic P2X4 Receptor has Unique Properties in the Heart by Mediating the Negative Chronotropic Effect of ATP While Increasing the Ventricular Inotropy.

Authors:  Bruno Bragança; Sílvia Nogueira-Marques; Fátima Ferreirinha; Ana Patrícia Fontes-Sousa; Paulo Correia-de-Sá
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.